WO2010102393A1 - Dérivés de 2-indolylimidazo[4,5-d]phénanthroline et leur utilisation pour inhiber l'angiogenèse - Google Patents
Dérivés de 2-indolylimidazo[4,5-d]phénanthroline et leur utilisation pour inhiber l'angiogenèse Download PDFInfo
- Publication number
- WO2010102393A1 WO2010102393A1 PCT/CA2010/000337 CA2010000337W WO2010102393A1 WO 2010102393 A1 WO2010102393 A1 WO 2010102393A1 CA 2010000337 W CA2010000337 W CA 2010000337W WO 2010102393 A1 WO2010102393 A1 WO 2010102393A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- alkyl
- hydrogen
- halogen
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 80
- HQGNWGOFTUIVSX-UHFFFAOYSA-N 6-(1H-indol-2-yl)-8,11,15,17-tetrazatetracyclo[8.7.0.01,14.04,9]heptadeca-2,4(9),5,7,10,12,14,16-octaene Chemical class N1C(=CC2=CC=CC=C12)C=1C=C2C=CC34C(C=CN=C3C2=NC=1)=NC=N4 HQGNWGOFTUIVSX-UHFFFAOYSA-N 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 319
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 95
- 238000000034 method Methods 0.000 claims abstract description 80
- 238000011282 treatment Methods 0.000 claims abstract description 49
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 20
- 206010064930 age-related macular degeneration Diseases 0.000 claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 14
- 206010012689 Diabetic retinopathy Diseases 0.000 claims abstract description 8
- 208000004644 retinal vein occlusion Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 75
- 125000000217 alkyl group Chemical group 0.000 claims description 74
- 229910052739 hydrogen Inorganic materials 0.000 claims description 59
- 239000001257 hydrogen Substances 0.000 claims description 59
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 58
- 201000010099 disease Diseases 0.000 claims description 49
- 229910052736 halogen Inorganic materials 0.000 claims description 49
- 150000002367 halogens Chemical group 0.000 claims description 49
- 150000003839 salts Chemical class 0.000 claims description 34
- 208000035475 disorder Diseases 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims description 17
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 15
- 230000004614 tumor growth Effects 0.000 claims description 15
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 14
- 125000005842 heteroatom Chemical group 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 238000002512 chemotherapy Methods 0.000 claims description 12
- 206010027476 Metastases Diseases 0.000 claims description 10
- 230000009401 metastasis Effects 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 238000002648 combination therapy Methods 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 229910001573 adamantine Inorganic materials 0.000 claims description 7
- 210000001072 colon Anatomy 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000037841 lung tumor Diseases 0.000 claims description 5
- 230000004083 survival effect Effects 0.000 claims description 5
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 125000001145 hydrido group Chemical group *[H] 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 abstract description 29
- 208000037765 diseases and disorders Diseases 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 description 126
- 230000014509 gene expression Effects 0.000 description 63
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- 239000000203 mixture Substances 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 34
- 230000000694 effects Effects 0.000 description 32
- 108020004999 messenger RNA Proteins 0.000 description 31
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 29
- 238000012360 testing method Methods 0.000 description 29
- 238000000338 in vitro Methods 0.000 description 28
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- 239000000243 solution Substances 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 24
- 238000003556 assay Methods 0.000 description 23
- 102000016736 Cyclin Human genes 0.000 description 21
- 108050006400 Cyclin Proteins 0.000 description 21
- 239000003981 vehicle Substances 0.000 description 21
- 102000015735 Beta-catenin Human genes 0.000 description 19
- 108060000903 Beta-catenin Proteins 0.000 description 19
- 239000012071 phase Substances 0.000 description 19
- 206010009944 Colon cancer Diseases 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 18
- 239000000725 suspension Substances 0.000 description 17
- -1 MTF-I Proteins 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 210000002889 endothelial cell Anatomy 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- 239000000460 chlorine Chemical group 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 238000010561 standard procedure Methods 0.000 description 13
- 102000040945 Transcription factor Human genes 0.000 description 12
- 108091023040 Transcription factor Proteins 0.000 description 12
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 229910052725 zinc Inorganic materials 0.000 description 12
- 239000011701 zinc Substances 0.000 description 12
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 11
- 239000005695 Ammonium acetate Substances 0.000 description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 11
- 229960000583 acetic acid Drugs 0.000 description 11
- 229940043376 ammonium acetate Drugs 0.000 description 11
- 235000019257 ammonium acetate Nutrition 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 201000005296 lung carcinoma Diseases 0.000 description 11
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000010261 cell growth Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 238000002493 microarray Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 8
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 229940126214 compound 3 Drugs 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 230000002491 angiogenic effect Effects 0.000 description 7
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000011580 nude mouse model Methods 0.000 description 7
- 229920001983 poloxamer Polymers 0.000 description 7
- 241000182988 Assa Species 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 101001139146 Homo sapiens Krueppel-like factor 2 Proteins 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 102100020675 Krueppel-like factor 2 Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000001772 anti-angiogenic effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 231100000682 maximum tolerated dose Toxicity 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- GQXXBWDAABZSHM-UHFFFAOYSA-N 8,11,15,17-tetrazatetracyclo[8.7.0.01,14.04,9]heptadeca-2,4(9),5,7,10,12,14,16-octaene Chemical compound C1=C2C=CC34C(C=CN=C3C2=NC=C1)=NC=N4 GQXXBWDAABZSHM-UHFFFAOYSA-N 0.000 description 5
- 208000022873 Ocular disease Diseases 0.000 description 5
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 5
- 241000906446 Theraps Species 0.000 description 5
- 108091008605 VEGF receptors Proteins 0.000 description 5
- 239000004037 angiogenesis inhibitor Substances 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000001028 anti-proliverative effect Effects 0.000 description 5
- 239000007900 aqueous suspension Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 238000002247 constant time method Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000004088 microvessel Anatomy 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000012447 xenograft mouse model Methods 0.000 description 5
- 239000011592 zinc chloride Substances 0.000 description 5
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 4
- 102100031782 Metallothionein-1L Human genes 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 238000012809 post-inoculation Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- RLQLBZDVAGJSFK-UHFFFAOYSA-N 2-(4-fluorophenyl)-1h-indole-3-carbaldehyde Chemical compound C1=CC(F)=CC=C1C1=C(C=O)C2=CC=CC=C2N1 RLQLBZDVAGJSFK-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241001192665 Anous Species 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- KMOCDFSQRUHBMN-UHFFFAOYSA-N C(c1ccccc1)[n]1c2ccccc2c(-c2nc(c3c(c4ncccc44)nccc3)c4[nH]2)c1 Chemical compound C(c1ccccc1)[n]1c2ccccc2c(-c2nc(c3c(c4ncccc44)nccc3)c4[nH]2)c1 KMOCDFSQRUHBMN-UHFFFAOYSA-N 0.000 description 3
- OQHUKYDTDIUWEQ-UHFFFAOYSA-N Clc(cc1)cc2c1[nH]cc2-c1nc(c2c(c3c4cccn3)nccc2)c4[nH]1 Chemical compound Clc(cc1)cc2c1[nH]cc2-c1nc(c2c(c3c4cccn3)nccc2)c4[nH]1 OQHUKYDTDIUWEQ-UHFFFAOYSA-N 0.000 description 3
- 239000004150 EU approved colour Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical group CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001023 pro-angiogenic effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 231100000456 subacute toxicity Toxicity 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- BFCDFTHTSVTWOG-PXNSSMCTSA-N (1r,2s)-2-(octylamino)-1-(4-propan-2-ylsulfanylphenyl)propan-1-ol Chemical compound CCCCCCCCN[C@@H](C)[C@H](O)C1=CC=C(SC(C)C)C=C1 BFCDFTHTSVTWOG-PXNSSMCTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- PEENKJZANBYXNB-UHFFFAOYSA-N 5-bromo-1h-indole-3-carbaldehyde Chemical compound BrC1=CC=C2NC=C(C=O)C2=C1 PEENKJZANBYXNB-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WYFNLLXXDCJPJQ-UHFFFAOYSA-N CC(C)[n]1c(ccc(OC)c2)c2c(-c2nc3c(cccn4)c4c4ncccc4c3[nH]2)c1 Chemical compound CC(C)[n]1c(ccc(OC)c2)c2c(-c2nc3c(cccn4)c4c4ncccc4c3[nH]2)c1 WYFNLLXXDCJPJQ-UHFFFAOYSA-N 0.000 description 2
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 101150021185 FGF gene Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 201000002563 Histoplasmosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101710094503 Metallothionein-1 Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000009905 Neurofibromatoses Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
- 206010056293 Renal vein occlusion Diseases 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 239000012052 hydrophilic carrier Substances 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000003584 mesangial cell Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 201000004931 neurofibromatosis Diseases 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000008137 solubility enhancer Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000012289 standard assay Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 208000009999 tuberous sclerosis Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 239000002525 vasculotropin inhibitor Substances 0.000 description 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- VLHGDCJIDNVRFM-UHFFFAOYSA-N 2-(4-fluorophenyl)-1h-indole Chemical compound C1=CC(F)=CC=C1C1=CC2=CC=CC=C2N1 VLHGDCJIDNVRFM-UHFFFAOYSA-N 0.000 description 1
- WBUVFDFTUTYHCU-MDZDMXLPSA-N 2-[(e)-2-(furan-2-yl)ethenyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1\C=C\C1=CC=CO1 WBUVFDFTUTYHCU-MDZDMXLPSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KXRGBILEIVWKAL-UHFFFAOYSA-N 3-chloro-5-phenyl-1,2-oxazole Chemical compound O1N=C(Cl)C=C1C1=CC=CC=C1 KXRGBILEIVWKAL-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000007848 Arts syndrome Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283724 Bison bonasus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- NKSCKNPZMJQYGB-UHFFFAOYSA-N C(CC1)CC1[n]1c2ccccc2c(-c2nc3c(cccn4)c4c4ncccc4c3[nH]2)c1 Chemical compound C(CC1)CC1[n]1c2ccccc2c(-c2nc3c(cccn4)c4c4ncccc4c3[nH]2)c1 NKSCKNPZMJQYGB-UHFFFAOYSA-N 0.000 description 1
- DKVZKVQYFVLMFB-UHFFFAOYSA-N CC(C)(C)c([nH]c1ccccc11)c1-c1nc2c(cccn3)c3c3ncccc3c2[nH]1 Chemical compound CC(C)(C)c([nH]c1ccccc11)c1-c1nc2c(cccn3)c3c3ncccc3c2[nH]1 DKVZKVQYFVLMFB-UHFFFAOYSA-N 0.000 description 1
- WFQMUEFSBCRKHH-UHFFFAOYSA-N CC(C)[n]1c(cccc2)c2c(-c2nc3c(cccn4)c4c4ncccc4c3[nH]2)c1 Chemical compound CC(C)[n]1c(cccc2)c2c(-c2nc3c(cccn4)c4c4ncccc4c3[nH]2)c1 WFQMUEFSBCRKHH-UHFFFAOYSA-N 0.000 description 1
- 101100450705 Caenorhabditis elegans hif-1 gene Proteins 0.000 description 1
- 101100258233 Caenorhabditis elegans sun-1 gene Proteins 0.000 description 1
- GUKNSMJSOBPUCY-UHFFFAOYSA-N Cc([nH]c(cc1)c2cc1Cl)c2-c1nc2c(cccn3)c3c3ncccc3c2[nH]1 Chemical compound Cc([nH]c(cc1)c2cc1Cl)c2-c1nc2c(cccn3)c3c3ncccc3c2[nH]1 GUKNSMJSOBPUCY-UHFFFAOYSA-N 0.000 description 1
- JASVCMBDRHXIPR-UHFFFAOYSA-N Cc([nH]c(cc1)c2cc1OC)c2-c1nc2c(CCC=N3)c3c3ncccc3c2[nH]1 Chemical compound Cc([nH]c(cc1)c2cc1OC)c2-c1nc2c(CCC=N3)c3c3ncccc3c2[nH]1 JASVCMBDRHXIPR-UHFFFAOYSA-N 0.000 description 1
- ADXDPUZHPVOYLA-UHFFFAOYSA-N Cc([n](C)c1ccccc11)c1-c1nc2c(cccn3)c3c3ncccc3c2[nH]1 Chemical compound Cc([n](C)c1ccccc11)c1-c1nc2c(cccn3)c3c3ncccc3c2[nH]1 ADXDPUZHPVOYLA-UHFFFAOYSA-N 0.000 description 1
- QBOHAINJUORADM-UHFFFAOYSA-N Cc([n](Cc1ccccc1)c(cc1)c2cc1F)c2-c1nc2c(cccn3)c3c3ncccc3c2[nH]1 Chemical compound Cc([n](Cc1ccccc1)c(cc1)c2cc1F)c2-c1nc2c(cccn3)c3c3ncccc3c2[nH]1 QBOHAINJUORADM-UHFFFAOYSA-N 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 206010063209 Chronic allograft nephropathy Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- OLRQMJRAKBOOFL-UHFFFAOYSA-N Clc(cc1)ccc1-c([nH]c1ccccc11)c1-c1nc2c(cccn3)c3c3ncccc3c2[nH]1 Chemical compound Clc(cc1)ccc1-c([nH]c1ccccc11)c1-c1nc2c(cccn3)c3c3ncccc3c2[nH]1 OLRQMJRAKBOOFL-UHFFFAOYSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 206010011715 Cyclitis Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 1
- 101100510266 Homo sapiens KLF4 gene Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010065630 Iris neovascularisation Diseases 0.000 description 1
- 101150070299 KLF4 gene Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 102100029698 Metallothionein-1A Human genes 0.000 description 1
- 101710196500 Metallothionein-1A Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 101100024583 Mus musculus Mtf1 gene Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- IFIFXODAHZPTEY-UHFFFAOYSA-N O=Cc1c(-c2ccccc2)[nH]c2c1cccc2 Chemical compound O=Cc1c(-c2ccccc2)[nH]c2c1cccc2 IFIFXODAHZPTEY-UHFFFAOYSA-N 0.000 description 1
- 231100000694 OECD Guidelines for the Testing of Chemicals Toxicity 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010055953 Scleroedema Diseases 0.000 description 1
- 108090000899 Serralysin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- MVIOINXPSFUJEN-UHFFFAOYSA-N benzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC=CC=C1 MVIOINXPSFUJEN-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KLLLJCACIRKBDT-UHFFFAOYSA-N c1c(-c2ccccc2)[nH]c2c1cccc2 Chemical compound c1c(-c2ccccc2)[nH]c2c1cccc2 KLLLJCACIRKBDT-UHFFFAOYSA-N 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 238000000006 cell growth inhibition assay Methods 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000007987 cellular zinc ion homeostasis Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 238000001152 differential interference contrast microscopy Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000437 effect on angiogenesis Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 229940093470 ethylene Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 231100000089 gene mutation induction Toxicity 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 238000013415 human tumor xenograft model Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- OLNJUISKUQQNIM-UHFFFAOYSA-N indole-3-carbaldehyde Chemical class C1=CC=C2C(C=O)=CNC2=C1 OLNJUISKUQQNIM-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001232 limbus corneae Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 231100000188 sister chromatid exchange Toxicity 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- BGRJTUBHPOOWDU-UHFFFAOYSA-N sulpiride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-UHFFFAOYSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229940091251 zinc supplement Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the im ention relates generalh to the field of anti-angiogenic therapeutics and in particular to the use of 2-indoh l imidazo[4,5-d]phenanthroline de ⁇ ati ⁇ es to inhibit angiogenesis
- Angiogenesis is the fundamental process b ⁇ which new blood ⁇ essels are formed and is essential to a ⁇ ariet ⁇ of normal bod ⁇ actmties such as reproduction, de ⁇ elopment and w ound repair
- the process is not completeh understood, it is behe ⁇ ed to im oh e a complex interplay of molecules which both stimulate and inhibit the growth of endothelial cells, the priman cells of the capillar ⁇ blood ⁇ essels
- the angiogenic process im oh es not onh increased endothelial cell proliferation but also comprises a cascade of additional e ⁇ ents, including protease secretion b ⁇ endothelial cells.
- Angiogenic stimuli for example, hy poxia or inflammaton cy tokines
- VEGF ascular endothelial growth factor
- FGF fibroblast growth factor
- Angiogenesis is a "common denominator" shared b ⁇ man ⁇ diseases including cancer, cardio ⁇ ascular disease, blindness, arthritis, complications of AIDS, diabetes, Alzheimer ' s disease and others
- cornea and cartilage are a ⁇ ascular in health ⁇ situations
- se ⁇ eral diseases im ohing these tissues are complicated b ⁇ the mass ⁇ e arm al of new blood ⁇ essels
- E ⁇ e angiogenic diseases include neo ⁇ ascular glaucoma, retrolental fibroplasia, macular degeneration and neo ⁇ ascula ⁇ zation of corneal grafts
- new capillaries formed in the retina im ade the ⁇ itreous, bleed, and cause blindness Joint angiogenic diseases include rheumatoid arthritis and arthrosis Psoriasis also exhibits pen ascula ⁇ zation at the surface of the skin Regulation of cell replication and/or differentiation is important in the maintenance of existing blood ⁇ essels, for example,
- VEGF vascular endothelial growth factor
- FIt-I and Flk-1/KDR receptors also called VEGF receptor 1 (VEGFRl) and VEGF receptor 2 (VEGFR2)
- VEGFRl and VEGFR2 VEGF receptor 1
- VEGFR2 VEGF receptor 2
- HIF-I is a heterodimeric basic-helix-loop-hehx-PAS transcription factor consisting of HIF-I alpha and HIF-I beta subunits HIF-I alpha expression and HIF-I transcriptional acti ⁇ it ⁇ increase exponential! ⁇ as cellular ox ⁇ gen concentration is decreased
- HIF-I is considered a critical mediator of the cellular response to h ⁇ poxia through its regulation of genes that control angiogenesis HIFs regulate the transcription of h ⁇ poxia-inducible genes b ⁇ binding poxia response elements (HRE) found in the promoter and enhancer regions of inducible genes H ⁇ poxia response elements ha ⁇ e been found in the promoter regions of genes encoding VEGF, the VEGF receptor FIt-I and nitric oxide sy nthases (associated with ⁇ asodilatation) It is behe ⁇ ed that hy
- Matrix metalloproteinases are also im oh ed in angiogenesis
- MMPs are a famih of zinc proteinases that digest the extracellular matrix and are implicated in a ⁇ ariet ⁇ of pathological conditions, including earh stages of angiogenesis, cardio ⁇ ascular diseases, and cancer metastasis
- MMPs including MMP-2 and MMP-9, are expressed in a ⁇ an et ⁇ of tissues
- Compounds that inhibit MMP acti ⁇ it ⁇ are thought to be useful for the treatment or propr ⁇ laxis of conditions that im oh e tissue breakdown including rheumatoid arthritis, osteoarthritis, gastric ulceration and cancer metastasis, as w ell as management of angiogenesis-dependent diseases
- Kruppel-hke factor KLF2 is a transcription factor that is expressed in lung, endothelial cells and h mphoc ⁇ tes and is essential for blood ⁇ essel lntegrit ⁇ and lung de ⁇ elopment KLF2 has been implicated in a number of processes including th ⁇ moc ⁇ te and T-cell migration (Carlson, C M .
- KLF2 has also been shown to inhibit VEGF-A-mediated angiogenesis and tissue edema in the nude ear mouse model of angiogenesis
- KLF2 expression retards VEGF-mediated calcium flux, proliferation and induction of pro-inflammator ⁇ factors in endothelial cells, and effect that is behe ⁇ ed to be due to inhibition of VEGFR2/KDR expression and promoter actmt ⁇ (Bhattachan a R, et al , J Biol Chem , 280 28848-51 (2005))
- An object of the present invention is to provide 2-indolvl imidazo[4,5-d]phenanthroline derivatives and uses thereof in the inhibition of angiogenesis.
- Rl, R2, R3 and R4 are independently selected from hydrogen, halogen, Cl - C4 alkyl, methoxy and phenyl;
- R5 is hydrogen, Cl - C4 alkyl. -CH 2 -phenyl or cyclopentyl;
- R6 is hydrogen, C l - C4 alkyl, phenyl optionally substituted with halogen or Cl - C4 alkyl, -CH 2 -heterocycle wherein the heterocycle is 6-membered ring comprising 1 or 2 heteroatoms selected from N and O and optionalh substituted with C l - C4 alk ⁇ 1.
- Figure 1 depicts the ability of compounds 3 and 7 to inhibit tumour growth in a non- small cell lung carcinoma xenograft model (A) and in a colon adenocarcinoma xenograft model (B), the abiht ⁇ of compound 7 to inhibit tumour grow th in a non-small cell lung carcinoma xenograft model (C), and the abiht ⁇ of compounds 7, 63, 64, 69, 72, 73, 74, 18 and 78 to inhibit tumour cell growth in a non-small cell lung carcinoma xenograft model (D)
- Figure 2 depicts the effect of compound 3 and compound 64 in the presence and absence of zinc on mRNA le ⁇ els in HT-29 cells in vitro for MTlA (A), MTF-I (B), C ⁇ din Dl (C) and KLF4 (D)
- Figure 3 depicts the effects of compound 7 on ⁇ anous transcription factors.
- A comparison of transcription factor actmt ⁇ in CCD- 18Co normal colon fibroblast cells and HT-29 colon carcinoma cells.
- B transcription factor actmt ⁇ in CCD- 18Co normal colon fibroblast cells and HT-29 colon carcinoma cells treated with 1 ⁇ M compound 7;
- C metallothionein 1 (MTlA) expression in HT-29 cells treated with 1 ⁇ M compound 7;
- HSF-I heat shock factor 1
- Figure 4 depicts the effect of compound 7 on niRNA levels of KLF4 (A) and (B), ⁇ - Catenin (C) and Cyclin Dl (D) in HT-29 colon cancer cells in vitro over time.
- Figure 5 depicts the effect of compound 7 on niRNA levels of KLF4 (A), ⁇ -Catenin (B) and Cyclin Dl (C) in NSCLC H226 cancer cells in vitro over time.
- Figure 6 depicts the effect of compound 7 on mRNA levels of KLF4 in vivo in tumours from a H226 mouse xenograft model over time.
- Tumor samples w ere excised at different time point after Lv. injection of single dose of 15mg/kg compound 7.
- Groups of 4 mice were injected and tumors were isolated at the time points indicated.
- Gene expression levels of KLF-4 were measured in each tumor using RT-PCR.
- Figure 7 (A-D) depicts the effect of compound 7 on mRNA levels of ⁇ -Catenin in vivo in tumours from the H226 mouse xenograft model described for Figure 6 over time.
- Figure 8 depicts the effect of compound 7 on mRNA levels of Cyclin Dl in vivo in tumours from the H226 mouse xenograft model described for Figure 6 over time.
- Figure 9 depicts the effect of compound 7 on mRNA levels of HIF-I ⁇ in H226 cancer cells in vitro over time.
- Figure 10 depicts the ability of compound 7 to decrease tumour size in a human lung carcinoma H226 xenograft in CD-I nude mice. The tumor growth profile after single injection of 15mg/kg compound 7 is shown.
- Figure 11 depicts the effect of compound 7 on mRNA levels of MTF-I (A-B), HIF- l ⁇
- C-D C-D
- MMP2 E
- VEGFR2 F
- Figure 12 depicts the results of immunohistochemistn anah sis demonstrating the effect of compound 7 (single treatment of 15 mg/kg) on micro ⁇ essel densit ⁇ in tumors (upper row of images) compared w ith a negat ⁇ e control group (low er row of images) Tumors w ere stained with anti-CD-31 antibodies to detect endothelial cells in sample sections
- Figure 13 depicts the effect of compound 7 in the presence (A) and absence (C) of zinc on HUVEC cell growth in vitro, the effect of a negat ⁇ e control compound is shown in (B)
- Figure 14 depicts the effect of compound 7 in the presence and absence of zinc on HUVEC tube formation in vitro HUVEC cells without (A-B) and with (C-D) ZnCl 2 DMSO control without ZnCl 2 (A). 0 5 ⁇ M of compound 7 without ZnCl 2 (B). DMSO control with ZnCl 2 (C). O 5 ⁇ M of compound 7 with ZnCl 2 (D). 5 ⁇ M of negat ⁇ e control treated cells (E)
- Figure 15 depicts the abiht ⁇ of compound 7 to pre ⁇ ent tumor growth in human tumor xenograft models.
- A model using H226 lung carcinoma cells and treatment with 15 mg/kg compound 7 or ⁇ ehicle control.
- B model using HOP92 lung carcinoma cells and treatment with 10 mg/kg compound 7 or ⁇ ehicle control.
- C model using H460 lung carcinoma cells and treatment with 7 5 mg/kg compound 7 or ⁇ ehicle control (1 C ⁇ cle).
- D model using H226 lung carcinoma cells and treatment with 10 mg/kg compound 7 or ⁇ ehicle control All results w ere significant p ⁇ 0 05
- the present inv ention relates to 2-indoh l imidazo[4,5-d]phenanthroline compounds of general Formula I, which, as demonstrated herein, are capable of inhibiting angiogenesis
- pro ⁇ ides for methods and uses of compounds of Formula I for inhibiting angiogenesis Angiogenesis is a process in a number of diseases and disorders and another embodiment of the in ⁇ ention therefore pro ⁇ ides for methods and uses of compounds of Formula I to inhibit angiogenesis and thereb ⁇ facilitate the treatment of angiogenesis-associated diseases 01 disoideis
- compounds of Formula I are capable of reducing expression of ⁇ ascular endothelial growth factor receptor 2 (VEGFR2)
- VEGFR2 ⁇ ascular endothelial growth factor receptor 2
- methods and uses of the compounds of Formula I for reducing expression of VEGFR2 m vivo or m vitro are pro ⁇ ided VEGF and its receptors (VEGFRl/Flt-1 and VEGFR2/F1L-1/KDR) are known to be im oh ed in regulation of angiogenesis in ⁇ anous disease contexts
- Actu ation of VEGFR2 stimulates angiogenesis, while VEGFRl actu ation appears to pla> a dual function b ⁇ either stimulating angiogenesis or suppressing angiogenesis
- the compounds of Formula I are capable of reducing the expression of Hy poxia-inducible factor- 1 (HIF- l ⁇ ) and the inv ention further pro ⁇ ides for methods and uses of the compounds of Formula I for reducing expression of HIF- l ⁇ m vivo or m vitro
- the in ⁇ ention also contemplates application of the compounds of Formula I in ⁇ arious non- therapeutic situations in which inhibition of angiogenesis is required
- halogen refers to fluorine, bromine, chlorine, and iodine atoms.
- C 1 -C4 alkyl refers to a straight chain or branched alkyl group of one to four carbon atoms. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl. see- but ⁇ 1 and tert-butyl (t-butyl).
- alkoxy refers to the group -OR, w here R is C1-C4 alkyl.
- heterocycle refers to a saturated carbocyclic group having a single ring and including at least one hetero atom, such as N, O or S, within the ring.
- cycloalkyl refers to a cyclic or poly cyclic alkyl group containing 3 to 15 carbon atoms.
- therapy and treatment refer to an intervention performed w ith the intention of alleviating the symptoms associated w ith, preventing the development of, or altering the pathology of a disease, disorder or condition.
- therapy and treatment are used in the broadest sense, and include the prevention (prophylaxis), moderation, management, reduction, or curing of a disease, disorder or condition at various stages. Prevention or reduction of the progression of a disease, disorder or condition is encompassed by these terms. Also encompassed by these terms is an intervention resulting in an alteration of physiology and/or biochemistry of a living subject.
- Those in need of therapy/treatment include those already having the disease, disorder or condition as w ell as those prone to, or at risk of developing, the disease, disorder or condition and those in whom the disease, disorder or condition is to be prevented.
- the therapeutic application of compounds of the invention therefore, refers to a therapy or treatment, as defined herein.
- subject or "patient,” as used herein, refer to an animal in need of treatment, including humans and other mammals.
- Administration of the compounds of Formula I "in combination with " one or more further therapeutic agents, is intended to include simultaneous (concurrent) administration and consecutive administration. Consecutive administration is intended to encompass various orders of administration of the therapeutic agent(s) and the compound(s) to the subject.
- inhibitor. means to reduce, halt or hold in check, and thus inhibition may be complete or partial and may be of short or long term duration.
- the term may be used in the context of inhibiting a process or action already begun or it may be used in the context of inhibiting initiation of a process or action.
- the term "about" refers to approximately a +/-10% variation from a given value. It is to be understood that such a variation is always included in any given value provided herein, whether or not it is specifically referred to.
- the present invention provides compounds of the general Formula I:
- Rl, R2, R3, R4 are independently selected from hydrogen; halogen; C 1-C4 alkyl; C 1 -C4 alkoxy and phenyl;
- R5 is hydrogen; C 1-C4 alkyl; C1-C4 alkyl substituted with phenyl; or cyclopentyl;
- R6 is hydrogen; halogen; C1-C4 alkyl; C 1-C4 alkyl substituted with C5-C6 heterocycloalkyl wherein the heteroatom is N; phenyl; phenyl substituted with C l- C4 alkyl or halogen; C5 -C6 cycloalkyl; C5-C6 heterocycloalkyl; or adamantine.
- Rl, R2, R3 and R4 are independently selected from hydrogen, halogen, Cl - C4 alkyl. methoxy and phenyl;
- R5 is hydrogen, Cl - C4 alkyl. -CH 2 -phenyl or cyclopentyl;
- R6 is hydrogen, C l - C4 alkyl, phenyl optionally substituted with halogen or Cl - C4 alkyl, -CFb-heterocycle therein the heterocycle is 6-membered ring comprising 1 or 2 heteroatoms selected from N and O and optionalh substituted with C 1 - C4 alkyl, C5 - C6 cycloalkyl or adamantane.
- Rl is hydrogen, halogen, or C 1 - C4 alkyl; R3 is hydrogen; and
- R2, R4, R5 and R6 are as defined abo ⁇ e.
- Rl is hydrogen, halogen or C 1 - C4 alkyl
- R2 and R4 are independently selected from hydrogen, halogen, Cl - C4 alkyl and methoxy;
- R3 is hydrogen
- R5 is hydrogen, Cl - C4 alkyl or cyclopentyl
- R6 is hydrogen, C l - C4 alkyl, phem l optionalh substituted with halogen or Cl - C4 alkyl, -CFb-heterocycle wherein the heterocycle is 6-membered ring comprising a N heteroatom, cyclopentyl or adamantane.
- Rl is hydrogen, halogen or C 1 - C4 alkyl
- R2 and R4 are independently selected from hydrogen, halogen, Cl - C4 alkyl and methoxy; R3 is hydrogen;
- R5 is hydrogen, Cl - C4 alkyl or cyclopentyl
- R6 is hydrogen, C l - C4 alkyl, phenyl optionally substituted with halogen or Cl - C4 alkyl, -CFb-heterocycle therein the heterocycle is 6-membered ring comprising a N heteroatom, c ⁇ clopent ⁇ 1 or adamantine, and at least two of Rl, R2, R4, R5 and R6 are other than hydrogen.
- Rl, R2, R3, R4 are independently hydrogen; halogen; or C 1-C4 alkyl; R5 is hydrogen; and R6 is Cl-C4 alkyl.
- the compounds of general Formula I include a compound of Formula II :
- R2 is halogen or methoxy; and R6 is Cl-C4 alkyl.
- R2 is halogen; and R6 is Cl-C4 alkyl.
- R2 is halogen; and R6 is methyl, isopropyl or t-butyl.
- R2 is F or Br. and R6isCl-C4alk ⁇ l
- R2 is F or Br.
- R6 is meth ⁇ 1, isoprop ⁇ 1 or t-but ⁇ 1
- the compound is compound 7 or a derivative thereof.
- a derivative thereof in this context can be, for example, a compound of Formula I wherein: Rl, R3, R4, R5 and R7 are H; R2 is halogen; and R6 is Ci-C 4 alkyl.
- the present invention includes various salts of the compounds defined by Formula I, including pharmaceutically acceptable salts.
- Compounds according to the present invention can possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly react with a number of organic and inorganic bases, and organic and inorganic acids, to form pharmaceutical! ⁇ acceptable salts.
- salts refers to a salt that is substantialh non-toxic to living organisms.
- Typical pharmaceutical! ⁇ acceptable salts include those salts prepared by reaction of the compound of the present invention with a pharmaceutically acceptable mineral or organic acid or an organic or inorganic base. Such salts are known as acid addition and base addition salts.
- Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulphuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulphonic acid, methanesulphonic acid, oxalic acid.
- Salts of amine groups may also comprise quarternary ammonium salts in which the amino nitrogen carries a suitable organic group such as an alkyl, lower alkenyl, substituted lower alkenyl, lower alkynyl, substituted lower alkynyl, or aralkyl moiety.
- Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like.
- Bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like.
- the particular counter ion forming a part of a salt of this invention is usually not of a critical nature, so long as the salt as a whole is pharmacologically acceptable and as long as the counter ion does not contribute undesired qualities to the salt as a whole.
- the compound of Formula I is provided as a pharmaceutically acceptable salt. In another embodiment, the compound of Formula I is provided in the form of a pharmaceutically acceptable hydrochloric salt.
- the present invention further encompasses the pharmaceutically acceptable solvates of a compound of Formula I.
- Man ⁇ of the compounds of Formula I can combine with solvents such as water, methanol, ethanol and acetonitrile to form pharmaceutically acceptable solvates such as the corresponding hydrate, methanolate, ethanolate and acetonitrilate.
- the compounds of Formula I may have multiple asymmetric (chiral) centres. As a consequence of these chiral centres, the compounds occur as racemates, mixtures of enantiomers and as individual enantiomers, as well as diastereomers and mixtures of diastereomers. All asymmetric forms, individual isomers and combinations thereof, are within the scope of the present invention.
- compounds of Formula I are prepared via solution or solid phase synthesis, by reacting a dione of Formula III with the aldehyde (IV) in the presence of ammonium acetate in acetic acid (see, for example, Krieg et a L,
- the compounds of Formula (III) and (IV) are either commercially available or may be prepared using standard procedures known to a person skilled in the relevant art.
- Compounds of Formula (III), for example, can be prepared by several general synthetic methods, such as those as described by: Fischer et. al (J. Am. Chem. Soc. 83:4208-4210 (1961)); Guijarro et al. (J. Am. Chem. Soc. 121 :4155-4157 (1999)); Chi et. al. (Synth. Comm. 24(15):2119-2122 (1994)); Armesto et. al. (Synthesis, 799-801 (1988)); Yamada et. al. (Bull. Soc Chem.
- Compounds of Formula (IV) can be prepared by general synthetic methods described by Vilsmeier et. al. (Chem. Ber. 91:850-861 (1958) and Synthesis 8:641-645 (1985)).
- compounds of formula (IV) can be prepared by reacting a compound of formula (V) w ith POCI3 in dimethylformamide (DMF) as shown below:
- the separation and purification of the imidazo[4,5-d]phenanthroline products is generalh based on their property to form w ater-soluble salts
- the impurities are extracted from the obtained solution with a nonpolar soh ent the aqueous la ⁇ er is basified and the separated imidazo[4,5- d]phenanthroline is filtered and recn stalhzed from a suitable soh ent
- compounds of Formula I are capable of inhibiting angiogenesis
- the compounds of Formula I are capable of reducing expression of VEGFR2
- the compounds of Formula I are capable of reducing expression of HIF-I ⁇
- the abiht ⁇ of a candidate compound of Formula I to inhibit angiogenesis m vitro and m vivo can be tested using standard techniques known in the art Similarh , the abilit ⁇ of the compounds to reduce expression of VEGFR2 and/or reduce expression of HIF- l ⁇ can be tested using standard techniques Exemplar ⁇ methods of testing candidate compounds of Formula I are pro ⁇ ided below and in the Examples included herein One skilled in the art will understand that other methods of testing the compounds are known in the art and are also suitable for testing candidate compounds
- a In vitro Testing ⁇ ) Ability to Inhibit Angiogenesis A number of standard techniques are suitable for assessing the ability of candidate compounds of Formula I to inhibit angiogenesis in vitro.
- a candidate compound of Formula I to inhibit proliferation of endothelial cells can be tested as follows. Cells of a specific test cell line are grown to a suitable density (e.g. approximately 1 x 10 4 ) and various concentrations of the candidate compound are added. After an appropriate incubation time (typically between about 48 to 74 hours), cell survival is assessed, for example, by assaying for tetrazolium salt (or modified tetrazolium salt) cleavage, or by using the resazurin reduction test (see Fields & Lancaster (1993) Am. Bwtechnol. Lab. 11 :48-50; O ' Brien et al., (2000) Eur J. Biochem.
- Inhibition of cell proliferation is determined by comparison of cell survival in the treated culture with cell survival in one or more control cultures, for example, cultures not pre-treated with the candidate compound, those pre-treated with a control vehicle and/or those pre-treated with a control compound (typically a known therapeutic).
- metabolic activity can also be used to assess the effect of candidate compounds on cell proliferation, given that proliferating cells tend to be metabolically more active than resting cells.
- the migration and differentiation of endothelial cells during angiogenesis can be studied in vitro using, for example, the Matrigel tube formation assay (see Grant et al., J. Cell. Physiol. 153:614 (1992) and Kubota Y, et al., J. Cell Biol. 107: 1589-98 (1988)).
- the Matrigel tube formation assay see Grant et al., J. Cell. Physiol. 153:614 (1992) and Kubota Y, et al., J. Cell Biol. 107: 1589-98 (1988)
- cell culture plates are coated with a Matrigel solution and then incubated at 37 0 C to promote gelling.
- HUVECs or other suitable cells are resuspended in growth media and added to each well.
- the candidate compound, positive control compound(s) for example.
- aFGF and/or bFGF aFGF and/or bFGF
- media alone a second control
- the plates are fixed and the length of the tubes/tube formation measured by microscopy, for example by differential interference contrast and/or fluorescence microscopy.
- suitable cell lines to assess the anti-angiogenic properties of candidate compounds include, but are not limited to, human umbilical vein endothelial cells (HUVECs), bovine aortic endothelial cells (BAECs), human coronary artery endothelial cells (HCAECs) and vascular smooth muscle cells.
- HUVECs can be isolated from umbilical cords using standard methods (see, for example, Jaffe et al. (1973) J. CIm. Invest. 52: 2745), or the ⁇ can be obtained from the ATCC or various commercial sources, as can other suitable endothelial cell lines.
- the candidate compound can be introduced into a selected cell line and the amount of mRNA transcribed from the gene of interest can be measured by standard techniques such as Northern blot analysis, RT-PCR, and the like.
- the amount of protein expressed from the target gene in the cell can be measured by standard techniques such as Western blot analysis.
- the amount of mRNA or protein produced in a cell treated with the candidate compound can then be compared with the amount produced in control cells and will provide an indication of how successfully the compound has inhibited expression of the target gene.
- Suitable control cells include, for example, untreated cells and/or cells treated with a control compound.
- the candidate compounds can be screened for their ability to modulate expression of the target gene(s) in a selected cell line using standard methods for screening expression of multiple genes ("expression profiling " ).
- expression profiling Such methods are well known in the art and include, for example, microarray analysis, such as high density microarray assays containing 10-fold more (for example, 19,000) human genes to identify suitable functional clusters of genes whose expression is affected by the compound.
- microarrays of short DNA sequences or oligonucleotides.
- Methods of constructing microarrays are well known in the art [see, for example, Ausubel. et a L, Current Protocols m Molecular Biology, John Wile ⁇ & Sons, Inc, NY. (1989 and updates)].
- microarrays can be custom made.
- Pre-made microarrays are also commercially available for man ⁇ organisms including, for example, GeneChip* (Affimetrix, Santa Clara, CA), AtlasTM (BD Biosciences-CLONTECH.
- RNA is isolated from cells treated with the candidate compound and from control cells. If necessary, the RNA can be amplified by conventional techniques to ensure a sufficient quantity for anal ⁇ sis.
- RNA is then hybridised to the microarray under suitable conditions and a routine anah sis of the microarray by commercially available scanners and software is conducted to identify genes whose expression is altered in the treated cells relative to the control cells.
- Suitable hybridization conditions can readily be determined by one skilled in the art using standard techniques. Following the identification of such other genes, mRNA quantitation and respective protein levels can also be evaluated to determine the extent of the effect of the compound on the genes under investigation.
- a number of assays are know n in the art for testing the ability of candidate compounds of Formula I to inhibit angiogenesis m vivo.
- the ability of the candidate compounds to inhibit endothelial cell migration can be determined using the chick chorioallantoic membrane (CAM) assay.
- CAM chick chorioallantoic membrane
- Matrigel plug assay and/or corneal micropocket assay are know n in the art for testing the ability of candidate compounds of Formula I to inhibit angiogenesis m vivo.
- the CAM assay is a standard assay that is used to evaluate the ability of a test compound to inhibit the growth of blood vessels into various tissues, i.e. both angiogenesis and neovascularization (see Brooks et ai, in Methods m Molecular Biology, VoI 129, pp 257-269 (2000), ed A R Hewlett Humana Press Inc , Totem a. NJ. Ausprunk et al , (1975) Am J Pathol , 79 597-618.
- the Mat ⁇ gel plug assa ⁇ is also a standard method for e ⁇ supering the anti-angiogenic properties of compounds m vivo (see, for example, Passaniti, et al ,(1992) Lab Invest 67 519-528)
- a test compound is introduced into cold liquid Mat ⁇ gel which, after subcutaneous miction into a suitable animal model, solidifies and permits penetration b ⁇ host cells and the formation of new blood ⁇ essels After a suitable period of time, the animal is sacrificed and the Mat ⁇ gel plug is reco ⁇ ered.
- the corneal micropocket assa ⁇ is usualh conducted in mice, rats or rabbits and has been described in detail b ⁇ others (see D'Amato, et al , (1994) Proc Natl, Acad Sci USA, 91 4082-4085. Koch et al , (1991) Agents Actions, 34 350-7.
- pellets for implantation are prepared from sterile r ⁇ dron poh mer containing a suitable amount of the test compound
- the pellets are surgicalh implanted into corneal stromal micropockets created at an appropriate distance medial to the lateral corneal limbus of the animal
- Angiogenesis can be quantitated at ⁇ a ⁇ ous times after pellet implantation through the use of stereomicroscop ⁇ T ⁇ picalh , the length of neo ⁇ essels generated from the limbal ⁇ essel ring tow ard the centre of the cornea and the width of the neo ⁇ essels are measured
- Candidate compounds of Formula I can also be tested for their effect on angiogenesis during tumor formation using standard xenograft models.
- mice bearing established tumors can be treated with the compound and. after a suitable time, sacrificed and the tumors removed. Density of microvessels in the excised tumors can be assessed using standard immunohistochemical techniques and compared to that of untreated tumors and/or tumors treated with a known anti-angiogenic agent.
- the compounds of Formula I can also be submitted to toxicity testing if desired. Toxicity tests for potential drugs are well-known in the art (see, for example, Hayes, A. W., ed., (1994), Principles and Methods of Toxicology, 3 rd ed.. Raven Press, NY; Maines, M., ed.. Current Protocols in Toxicology, John Wile ⁇ ' & Sons, Inc., NY).
- In vitro acute toxicity testing of a compound of Formula I can be performed using mammalian cell lines (see, for example, Ekw all, B., Ann. K Y. Acad. Sa., (1983) 407:64-77). Selection of an appropriate cell line is dependent on the potential application of the candidate compound and can be readily determined by one skilled in the art. For example, these tests include the treatment of human primary fibroblasts in vitro with the compounds of Formula I in the presence of a commercial carrier. Cells are then tested at different time points following treatment for their viability using a standard viability assay, such as the tn pan-blue exclusion assay, XTT or MTT assays.
- a standard viability assay such as the tn pan-blue exclusion assay, XTT or MTT assays.
- Cells can also be assayed for their ability to synthesize DNA, for example, using a thymidine incorporation assay, and for changes in cell cycle dynamics, for example, using a standard cell sorting assay in conjunction with a fluoroc ⁇ tometer cell sorter (FACS).
- FACS fluoroc ⁇ tometer cell sorter
- In vivo toxicity testing can be performed by standard methodology, for example, by injecting van ing concentrations of the candidate compound into an appropriate animal model. The compound can be injected once, or administration can be repeated over several days. The toxic effects of the compound can be evaluated over an appropriate time period by monitoring the mortality, changes in behavior, appearance, and bod ⁇ w eight of the animals. After the completion of the period of assessment, the animals can be sacrificed and the appearance and w eight of the relevant organs determined. If necessary, additional assessments of, for example, hematological profiles, histology, and liver enzyme analysis may be performed. An indication of the toxicity of a compound can also be obtained during the in vivo testing of
- the genotoxicity of compounds of Formula I can be assessed in vitro if necessary using standard techniques such as the Ames Assay to screen for mutagenic activity, the mouse lymphoma assay to determine the ability of a test article to induce gene mutation in a mammalian cell line, m vitro chromosomal aberration assays using, for example, Chinese hamster ovary cells (CHO) to determine any DNA rearrangements or damage induced by the test article.
- Other assays include the sister chromatid assay, which determines any exchange between the arms of a chromosome induced by the test article and m vitro mouse micronucleus assays to determine any damage to chromosomes or to the mitotic spindle.
- the genotoxicity of compounds of Formula I can also be assessed m vivo if necessary using the m vivo sister chromatid exchange assay, m vivo micronucleus assay, or the m vivo chromosomal abberation assay. Protocols for these and other standard assays are known in the art, for example, see OECD Guidelines for the Testing of Chemicals and protocols developed by the ISO.
- compositions comprising the compounds of Formula I will need to meet certain criteria in order to be suitable for human use and to meet regulatory requirements.
- standard in vitro and in vivo tests can be conducted to determine information about the metabolism and pharmacokinetic (PK) of the compositions and combinations (including data on drug-drug interactions w here appropriate) which can be used to design human clinical trials
- Phase I Phase II Studies are conducted to inv estigate the safet ⁇ , tolerabilit ⁇ and PK of the compounds and to help design Phase II studies, for example, in terms of appropriate doses, routes of administration, administration protocols
- Phase I studies allow the selection of safe dose le ⁇ els for Phase II studies
- An important factor in the protocol design of the Phase II studies is the adequate recruitment of the patient population to be studied based on stringent selection criteria defining the demographics (age, race and sex) of the stud ⁇ and the pre ⁇ ious medical histon of the patient
- a protocol for Phase II studies t ⁇ picalh specifies baseline data that can be used to characterise the population, to e ⁇ sine the success of randomization in achie ⁇ ing balance of important prognostic factors, and to allow for consideration of ad) usted anah ses
- Clinical biomarkers can be defined as follow s (Atkinson A et al CIm Pharmacol Ther 69, 89-95 (2001) Biological marker (biomarker) a characteristic that is ob)ecti ⁇ eh measured and e ⁇ supered as an indicator of normal biological process, pathogenic process, or pharmacological response to a therapeutic inten ention
- Clinical endpomt a characteristic or ⁇ anable that reflects how a patient feels or functions, or how long a patient sun i ⁇ es
- Surrogate endpomt biomarker intended to substitute for a clinical endpoint A clinical im estigator uses epidemiological, therapeutic, pathophy siological, or other scientific e ⁇ idence to select a surrogate endpoint that is expected to predict benefit, harm or the lack of benefit or harm
- the FDA defines a surrogate endpoint. or marker, as a laboraton measurement or sical sign that is used in therapeutic trials as a substitute for a clinicalh meaningful endpoint that is a direct measure of how a patient feels, functions or sur ⁇ i ⁇ e and is expected to predict the effect of therap ⁇
- Phase III trials focus on determining how the compound compares to the standard, or most wideh accepted, treatment
- patients are randomh assigned to one of tw o or more "arms "
- tw o arms for example, one arm will rece ⁇ e the standard treatment (control group) and the other arm will be treated with the test compound (in ⁇ estigational group)
- Phase IV trials can be used to further e ⁇ sinumeric dosage of the compound Phase IV trials are less common than Phase I, II and III trials and w ould take place after the compound has been appro ⁇ ed for standard use
- the in ⁇ ention pro ⁇ ides for methods of using and uses of compounds of Formula I to inhibit angiogenesis, to treat angiogenesis associated diseases or disorders, inhibit VEGFR2 expression and/or inhibit HIF- l ⁇ expression
- the compounds of Formula I can be used to inhibit angiogenesis m vitro or m vivo
- angiogenesis-associated diseases and disorders are terms used generalh to refer to a disease or disorder which occurs as a consequence of, or which results in, increased ⁇ ascula ⁇ zation in a tissue
- Angiogenesis maj be an actual cause of the disease/disorder or it maj be a condition resulting from the disease/disorder
- angiogenesis-associated diseases and disorders include, but are not limited to tumor-growth and/or metastasis, including solid tumors, Kaposi sarcoma, angiofibromas, retrolental fibroplasia, and hemangiomas.
- ocular diseases and disorders including keratoplasty angiogenesis, angiogenic glaucoma, macular degeneration (for example
- ALD diabetic retinopathy
- retinopathy of prematurity angiogenic corneal disorder
- pten gium retinal degeneration
- retrolental fibroplasias trachoma.
- corneal neo ⁇ ascula ⁇ zation corneal neo ⁇ ascula ⁇ zation
- choroidal neo ⁇ ascula ⁇ zation ⁇ clitis
- renal diseases including glomerulonephritis, diabetic nephropathy , malignant nephrosclerosis, thrombotic microangiopathic sy ndrome, transplant rejections and glomerulopathy .
- cerebro ⁇ ascular diseases including multiple sclerosis, experimental allergic encephalomy elitis, bacterial meningitis, ischemia, brain edema.
- fibrotic diseases including cirrhosis of the h ⁇ er. and mesangial cell proliferate e diseases.
- senile keratosis examples include senile keratosis, endometriosis, osteoporosis h mphangiogenesis, Sturge-Weber S ⁇ ndrome, neurofibromatosis tuberous sclerosis and asthma
- the in ⁇ ention pro ⁇ ides for the use of the compounds of Formula I to inhibit tumor-associated angiogenesis Angiogenesis is critical to the growth and metastasis of solid tumors Inhibition of angiogenesis in a cancer context, therefore, helps to stabilise the disease b ⁇ reducing or halting the grow th and/or spread of the tumor Accordingly , one embodiment of the in ⁇ ention pro ⁇ ides for the use of the compounds of Formula I to stabilise a cancer in a patient b ⁇ inhibiting tumor-associated angiogenesis Another embodiment pro ⁇ ides for the use of the compounds of Formula I to inhibit metastasis of a solid tumor in a patient, and potentialh contain the neoplastic growth at the priman site, b ⁇ inhibiting tumor-associated angiogenesis A further embodiment pro ⁇ ides for the use of the compounds of Formula I to increase progression-free sur ⁇ i ⁇ al in a patient b ⁇ inhibiting tumor-associated angiogenesis
- pro ⁇ ides for the use of the compounds of Formula I to reduce the recurrence of a solid tumor such as in ⁇ asi ⁇ e breast carcinoma
- Anti-angiogenic agents are known to increase the effica ⁇ of traditional cancer therapies, including chemotherapy and radiation therap ⁇
- pro ⁇ ides for the use of the compounds of Formula I as an antiangiogenic component of a combination therap ⁇ for the treatment of cancer Another embodiment pro ⁇ ides for the use of the compounds of Formula I in combination with one or more chemotherapeutic to treat cancer Examples of suitable chemotherapeutics include, but are not limited to, carboplatin, cisplatin, c ⁇ clophosphamide, danorubicin, docetaxel, doxorubicin,
- Anti-angiogenic agents are parti cularh useful in combination with metronomic chemotherapy
- Metronomic chemotherapy in ⁇ oh es the frequent administration of one or more chemotherapeutic agents at doses significanth below the maximum tolerated dose (MTD) with no prolonged drug-free breaks
- the main targets of metronomic chemotherapy are the endothelium or tumor stroma rather than the tumor itself and the efficac ⁇ of metronomic chemotherapy can be enhanced b ⁇ combining the chemotherapy w ith an anti-angiogenic agent Accordingly , one embodiment of the in ⁇ ention pro ⁇ ides for the use of compounds of Formula 1 in combination with metronomic chemotherapy for the treatment of cancer
- the in ⁇ ention pro ⁇ ides for the use of the compounds of Formula I in the treatment of non-cancerous angiogenesis associated disorders such as angiogenesis-associated ocular diseases and disorders, angiogenesis-associated immune disorders, angiogenesis-associated cardio ⁇ ascular diseases, angiogenesis-associated skin disorders, angiogenesis-associated chronic inflammaton disease, angiogenesis- associated renal diseases, angiogenesis-associated cerebro ⁇ ascular diseases, angiogenesis-associated fibrotic diseases, mesangial cell proliferate e diseases, senile keratosis, endometriosis, osteoporosis h mphangiogenesis. Sturge-Weber sy ndrome.
- the invention provides for the use of the compounds of Formula I in the treatment of ocular diseases characterized by undesired neovascularization, for example, age-related macular degeneration (AMD), diabetic retinopathy, corneal neovascularization, choroidal neovascularization, cyclitis. Hippei- Lindau Disease, retinopathy of prematurity, pterygium, histoplasmosis, iris neovascularization, macular edema, glaucoma-associated neovascularization. Purrs cher ' s retinopathy, renal vein occlusion and the like.
- AMD age-related macular degeneration
- diabetic retinopathy diabetic retinopathy
- corneal neovascularization corneal neovascularization
- choroidal neovascularization cyclitis.
- Hippei- Lindau Disease retinopathy of prematurity, pterygium, histoplasmos
- compounds of Formula I are capable of reducing expression of vascular endothelial growth factor receptor 2 (VEGFR2). Accordingly, in one embodiment, the use of the compounds of Formula I for reducing expression of VEGFR2 in vivo or in vitro is provided.
- Inhibitors of VEGF and its receptors have been shown to be effective in controlling angiogenesis in various disease contexts, including for example, solid tumors (such as colorectal, breast, lung and kidney tumors), AMD, diabetic retinopathy and renal vein occlusion.
- the invention provides for the use of the compounds of Formula I in the treatment of angiogenesis associated diseases and disorders for which treatment with VEGF inhibitors is known to be effective, such as growth or metastasis of solid tumors (including colorectal, breast, lung and kidney). AMD, diabetic retinopathy and retinal vein occlusion.
- the invention provides for the use of the compounds of Formula I for reducing expression of HIF-l ⁇ m vivo or m vitro.
- the compounds of the present invention are typically formulated prior to administration.
- the present invention thus provides pharmaceutical compositions comprising one or more compounds of Formula I and a pharmaceutically acceptable carrier, diluent, or excipient.
- the pharmaceutical compositions are prepared by known procedures using well-known and readily available ingredients.
- Compounds of the general Formula I or pharmaceutical compositions comprising the compounds may be administered orally, topically, parenteral! ⁇ , by inhalation or spray. or rectalh in dosage unit formulations containing conv entional non-toxic pharmaceutical! ⁇ acceptable carriers, ad)u ⁇ ants and ⁇ ehicles
- the act ⁇ e compound is incorporated into an acceptable ⁇ ehicle to form a composition for topical administration to the affected area, such as hy drophobic or h ⁇ drophihc creams or lotions, or into a form suitable for oral, rectal or parenteral administration, such as s ⁇ nips, elixirs, tablets, troches, lozenges, hard or soft capsules, pills, suppositories, oih or aqueous suspensions, dispersible pow ders or granules, emulsions, in)ectables, or solutions
- the present im ention also pro ⁇ ides for pharmaceutical compositions comprising one or more of the compounds of Formula I and a ⁇ ehicle, such as an artificial membrane ⁇ esicle (including a liposome, lipid micelle and the like), microparticle or microcapsule
- a ⁇ ehicle such as an artificial membrane ⁇ esicle (including a liposome, lipid micelle and the like), microparticle or microcapsule
- compositions intended for oral use ma ⁇ be prepared in either solid or fluid unit dosage forms
- Fluid unit dosage form can be prepared according to procedures known in the art for the manufacture of pharmaceutical compositions and such compositions ma ⁇ contain one or more agents selected from the group consisting of sw eetening agents, fla ⁇ ou ⁇ ng agents, colouring agents and preserv ing agents in order to pro ⁇ ide pharmaceuticalh elegant and palatable preparations
- An elixir is prepared b ⁇ using a h ⁇ droalcoholic (e g , ethanol) ⁇ ehicle with suitable sw eeteners such as sugar and saccharin, together w ith an aromatic fla ⁇ o ⁇ ng agent
- Suspensions can be prepared w ith an aqueous ⁇ ehicle with the aid of a suspending agent such as acacia, tragacanth, meth ⁇ lcellulose and the like
- Solid formulations such as tablets contain the act ⁇ e ingredient in admixture with nontoxic pharmaceuticalh acceptable excipients that are suitable for the manufacture of tablets
- excipients ma ⁇ be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate granulating and disintegrating agents for example, corn starch, or alginic acid binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc and other com entional ingredients such as dicalcium phosphate, magnesium aluminum silicate, calcium sulfate, starch, lactose. meth ⁇ lcellulose, and functionally similar materials.
- inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate granulating and disintegrating agents for example, corn starch, or alginic acid binding agents, for example
- the tablets may be uncoated or the ⁇ may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with w ater or an oil medium, for example peanut oil, liquid paraffin or olive oil.
- Soft gelatin capsules are prepared by machine encapsulation of a slum of the compound with an acceptable vegetable oil, light liquid petrolatum or other inert oil.
- Aqueous suspensions contain active materials in admixture w ith excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxylmethylcellulose, methyl cellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia: dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example poh oxy ethylene stearate, or condensation products of ethylene oxide w ith long chain aliphatic alcohols, for example hepta-decaeth ⁇ leneox ⁇ cetanol, or condensation products of ethylene oxide w ith partial esters derived from fatly acids and a hexitol such as polyox ⁇ ethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or ⁇ -propyl- p-hs droxy benzoate, one or more colouring agents, one or more flavouring agents or one or more sweetening a • *g£>e v nts, such as sucrose or saccharin.
- preservatives for example ethyl, or ⁇ -propyl- p-hs droxy benzoate
- colouring agents for example ethyl, or ⁇ -propyl- p-hs droxy benzoate
- flavouring agents for example sucrose or saccharin.
- sweetening a • *g£>e v nts such as sucrose or saccharin.
- suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example peanut oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oil ⁇ suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
- Sweetening agents such as those set forth above, and flavouring agents may be added to provide palatable oral preparations.
- These compositions may be preserv ed by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of w ater provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preserv atives.
- a dispersing or wetting agent, suspending agent and one or more preserv atives are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.
- compositions of the invention may also be in the form of oil-in- water emulsions.
- the oil phase may be a vegetable oil, for example olive oil or peanut oil, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhy drides, for example sorbitan monooleate, and condensation products of the said partial esters w ith ethylene oxide, for example poly oxy ethy lene sorbitan monooleate.
- the emulsions may also contain sweetening and flavoring agents.
- the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension.
- This suspension may be formulated according to known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above.
- the sterile injectable preparation may also be a sterile injectable solution or a suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1.3-butanediol.
- the acceptable vehicles and solvents that may be employ ed are water. Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventional! ⁇ employed as a solvent or suspending medium.
- any bland fixed oil may be employ ed including sy nthetic mono- or digh cerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- Adjuvants such as local anaesthetics, preservatives and buffering agents can also be included in the injectable solution or suspension.
- the compound of the general Formula I may be administered in the form of suppositories for rectal administration of the drug.
- These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and w ill therefore melt in the rectum to release the drug.
- suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and w ill therefore melt in the rectum to release the drug.
- Such materials include cocoa butter and polyethylene glycols.
- the compounds can be formulated into solutions, suspensions, and ointments appropriate for use in the eye (see, for example, Mitra (ed.), (1993) Ophthalmic Drug Delivery Systems, Marcel Dekker, Inc., New York, N.Y.; Havener, (1983) Ocular Pharmacology, CV. Mosby Co., St. Louis).
- compounds of Formula I that show poor solubility can be formulated with appropriate hydrophilic carriers, solubility enhancers and/or surfactants.
- hydrophilic carriers, solubility enhancers and surfactants include, but are not limited to, polyvinylpyrrolidone, polyethylene glycols (PEGs), poh propylene glycol (PPG), Plasdone-S630, carboxymethyl cellulose, hydroxypropyl cellulose, guar gum. xanthan gum, sodium alginate, methyl cellulose, HPMC, dextrin, cyclodextrins, galactomannan, Tween-80, Docusate sodium.
- Compounds of Formula I may be administered to a subject by a variety of routes depending on the disease or disorder to be treated, for example, the compounds may be administered orally, topically, parenteral! ⁇ , by inhalation or spray, or rectally in dosage unit formulations.
- parenteral as used herein includes subcutaneous injections. intradermal, intra-articular, intravenous, intramuscular, intravascular, intrasternal, intrathecal injection or infusion techniques.
- the present invention contemplates the administration of one or more compounds of Formula I either alone or in combination with other therapies.
- other therapies For example, with radiation or chemotherapy when administered to cancer patients, or with other standard therapeutics used in the treatment of the disease or disorder being treated.
- the dosage to be administered is not subject to defined limits, but it will usually be an effective amount. It will usually be the equivalent, on a molar basis of the pharmacologically active free form produced from a dosage formulation upon the metabolic release of the active free drug to achieve its desired pharmacological and physiological effects.
- the compositions may be formulated in a unit dosage form.
- unit dosage form refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Examples of ranges for the compound(s) in each dosage unit are from about 0.05 to about 100 mg, or more usually, from about 1.0 to about 50 m 1 gB.-
- Daily dosages of the compounds of the present invention w ill typically fall within the range of about 0.01 to about 100 mg/kg of bod ⁇ weight, in single or divided dose.
- the actual amount of the compound(s) to be administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.
- the above dosage range is given by w ay of example only and is not intended to limit the scope of the invention in any wa ⁇ .
- dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing harmful side effects, for example, by first dividing the larger dose into several smaller doses for administration throughout the day.
- it ma> be desirable to administer the compound at a dosage low er than the MTD For example, in those embodiments relating to the use of the compounds of Formula I in combination with metronomic chemotherap ⁇ , the compound ma ⁇ be administered at the MTD, shghth below the MTD or significant! ⁇ below the MTD
- kits containing one or more compounds of Formula I The contents of the kit can be 1 ⁇ ophihzed and the kit can additional! ⁇ contain a suitable soh ent for reconstitution of the 1 ⁇ ophihzed components
- Indmdual components of the kit w ould be packaged in separate containers and. associated with such containers, can be a notice in the form prescribed b ⁇ a go ⁇ ernmental agenc ⁇ regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects appro ⁇ al b ⁇ the agenc ⁇ of manufacture, for use or sale for human or animal administration
- the liquid solution can be an aqueous solution, for example a sterile aqueous solution
- the compounds ma ⁇ be formulated into a pharmaceutical! ⁇ acceptable s ⁇ ⁇ ngeable composition
- the container means ma ⁇ itself be an inhalant, s ⁇ ⁇ nge, pipette, e ⁇ e dropper, or other such like apparatus, from which the formulation ma ⁇ be applied to an infected area of the sub)ect. such as the lungs, iniected into an sub)ect. or e ⁇ en applied to and mixed with the other components of the kit
- kits or packs comprising one or more compound of the present im ention in combination with one or more standard therapeutic for combination therap ⁇ applications are also contemplated b ⁇ the present in ⁇ ention
- HT-29 colon carcinoma cells used in this example and subsequent examples w ere maintained as a monolayer in a growth medium; McCoy's 5A modified medium (Sigma. St. Louis, MO), supplemented with 2 mM L-glutamine (Gibco, Grand Island. NY), 10% fetal bovine serum (FBS) (Multicell, WISENT Inc. St-Bruno, QC), antibiotic-antimycotic (Multicell), at 37 0 C in a 5% CO 2 - humidified incubator. Cells w ere transferred onto 150mm tissue culture plates and grown until sub-confluency (70-80%) prior to their use.
- mice Groups of 3 ICR female mice were injected with one intra-peritoneal (i.p.) injection of
- the compounds to be tested were prepared to provide enough for one week at concentrations of 4.0 mg/ml and 2.0 mg/ml. Briefly, 50 mg of each compound w as dissolved in 1.25 ml of 100 % DMSO and diluted with 6.25 ml of Lutrol (30 % in water) and 5 ml water, to prepare a solution of 4mg/ml compound in 15% Lutrol in water. Next, 4 ml of each prepared solution w as further diluted with 4 ml of 15% Lutrol in water to provide the 2.0 mg/ml solution of each compound. For the vehicle control solution, 8 ml of 15% Lutrol in water w as prepared. Compounds at concentrations of 4.0 mg/ml and 2.0 mg/ml and the vehicle control were administered as described above. Toxicity w as evaluated based on mortality, changes in behaviour, appearance and weight and is shown in Table 2.
- EXAMPLE 12 IN VITRO ANTIPROLIFERATIVE ACTIVITY OF COMPOUNDS OF FORMULA I IN HT-29 COLON CARCINOMA CELLS
- EXAMPLE 13 IN VITRO ABILITY OF COMPOUNDS OF FORMULA I TO MODULATE CELL GROWTH INHIBITION IN HUMAN CANCER CELLS LINES
- IC50 Cell growth inhibition IC50 ( ⁇ M) by compounds of Formula I w as tested on various cancer cell types by XTT cell proliferation assay. Low or sub-micromolar IC50 was observed in different types of cancer as shown in Table 4. The growth inhibitor ⁇ effects of the compounds of Formula I as shown below for the melanoma cell line SK-MEL-2 w ere reproducible by Lorus Therapeutics Inc.
- IC50 values for compounds of Formula I in the breast cancer cell line MDA-MB- 435 were between 0.2 ⁇ M and 0.6 ⁇ M as shown below in Table 4.
- Table 4 Cell Growth Inhibition IG;o ( ⁇ M) by Compounds of Formula I in Different Cancer Cell Types
- EXAMPLE 14 IN VIVO EFFICACY OF COMPOUNDS OF FORMULA I IN LARGE-CELL LUNG CARCINOMA AND COLON CARCINOMA XENOGRAFT MODELS
- Tumor growth inhibition b ⁇ compounds of Formula I in mouse xenograft models is shown in Figure 1 Route of administration and schedule studies for non-small cell lung carcinoma (H460) ( Figure IA) and colon adenocarcinoma (HT-29) ( Figure IB), minimal effect ⁇ e dose for non-small cell lung carcinoma (H460) ( Figure 1C), and efficac ⁇ of optimized compounds of Formula I in non-small cell lung carcinoma (H460) ( Figure ID)
- EXAMPLE 15 IN VITRO ABILITY OF COMPOUND 64 TO MODULATE GENE EXPRESSION OF MTlA, MTF-I, CYCLIN Dl AND KLF4 IN HT-29 CELLS
- EXAMPLE 16 DIFFERENTIAL TRANSCRIPTION ACTIVITY IN NORMAL AND CANCER CELLS IN VITRO UPON TREATMENT WITH COMPOUND 7
- KLF4 is known to act as a transcriptional activator of several cell cycle inhibitors, as well as a transcriptional repressor of several genes encoding promoters of the cell cycle.
- the transcriptional activity of 50 transcription factors was investigated in colon carcinoma cells treated with 1 ⁇ M Compound 7 for between 2 and 16 hours. DNA-binding activities of the transcription factors were measured by Multiplex Transcription Factor Testing Service (Marligen Biosciences, Ijamsville, MD).
- Figure 3 A shows the differential transcriptional profile of colon carcinoma HT-29 cells and normal colon fibroblast CCD- 18Co cells after treatment w ith Compound 7. Altered activity of several transcription factors w as observed in colon cancer cells with no significant effect on normal cells; particularly the activation of transcription factors involved in tumor suppression and tumor promoters (Figure 3B).
- HSF-I Heat shock factor 1
- Figure 3 A & D Heat shock factor 1
- HSF-I is a known transcriptional regulator of KLF4 in response to stress, and can be negatively regulated by forming a complex w ith MTF-I.
- EXAMPLE 17 IN VITRO ABILITY OF COMPOUND 7 TO MODULATE GENE EXPRESSION OF KLF4, ⁇ -CATENIN AND CYCLIN Dl IN HT-29 CELLS
- HT-29 cells 5 X 10 5 cells in 5 niL volume of growth medium w ere seeded in 6-cm dishes and incubated overnight at 37 0 C.
- the medium w as removed and replaced with growth medium containing 0.1% DMSO vehicle control or 1 ⁇ M of Compound 7. After incubation for 4, 7, 16, or 24 hours, the cells w ere detached by trypsinization, collected by centrifugation and w ashed once with PBS.
- RNA w as extracted from cells by using TRIZOL (Invitrogen, Life Technologies, Carlsbad. CA), following manufacturer ' s instruction, and the level of KLF4 mRNA, ⁇ -catenin mRNA, and Cyclin Dl mRNA w as measured by real time PCR using the comparative CT method as follow s.
- First strand cDNA w as synthesized from 200 ng total RNA in Biometra Tpersonal Thermal Cycler (Abgene, UK), using pd(N)6 random hexamer (Amersham Biosciences, Piscataw ay, NJ) and SuperscriptTM II Reverse Transcriptase kit (Invitrogen) by following manufacturer ' s protocol.
- EXAMPLE 18 IN VITRO ABILITY OF COMPOUND 7 TO MODULATE GENE EXPRESSION OF KLF4, ⁇ -CATENIN, AND CYCLIN Dl IN H226 CELLS
- H226 cells 5 X K 5 cells in 5 mL volume of growth medium were seeded in 6-cm dishes and incubated overnight at 37 0 C. The medium was removed and replaced with growth medium containing 0.1% DMSO vehicle control or 1 ⁇ M of Compound 7. After incubation for 4, 7, 16, or 24 hours, the cells were detached by trypsinization, collected by centrifugation and washed once with PBS. Total RNA w as extracted from cells by using TRIZOL (Invitrogen, Life Technologies, Carlsbad. CA), following manufacturer ' s instruction, and the level of KLF4 mRNA, ⁇ -catenin mRNA, and Cyclin Dl mRNA w as measured by real time PCR using the comparative CT method as described in Example 17.
- TRIZOL Invitrogen, Life Technologies, Carlsbad. CA
- EXAMPLE 19 IN VIVO ABILITY OF COMPOUND 7 TO MODULATE GENE EXPRESSION OF KLF4, ⁇ -CATENIN, AND CYCLIN Dl IN A NSCLC CANCER XENOGRAFT MODEL
- Cyclin Dl is a downstream target of ⁇ -catenin, whose transcription is regulated by KLF4. As such, the involvement of the Wnt/ ⁇ -catenin signaling pathway in the mode of action of compound 7 w as investigated.
- ⁇ -catenin, cyclin D and KLF4 gene expression w as analyzed by RT-PCR in samples extracted from HT-29 colon cancer cells treated with Compound 7 in vitro, and from HT-29 xenograft tumors from treated CD-I nude mice.
- EXAMPLE 20 IN VITRO ABILITY OF COMPOUND 7 TO MODULATE GENE EXPRESSION OF HIF-l ⁇ IN H226 CELLS
- the ability of Compound 7 to modulate the mRNA level of HIF-I ⁇ genes in human non-small cell lung cancer H226 cells was determined in vitro as follows. H226 cells, 5 X 10 5 cells in 5 niL volume of growth medium were seeded in 6-cm dishes and incubated overnight at 37 0 C. The medium w as removed and replaced w ith growth medium containing 0.1% DMSO vehicle control or 1 ⁇ M of Compound 7. After incubation for 4, 7.
- RNA w as extracted from cells by using TRIZOL (Invitrogen, Life Technologies, Carlsbad. CA), following manufacturer ' s instruction, and the level of HIF- l ⁇ niRNA was measured by real time PCR using the comparative CT method as described in Example 17.
- Tumor growth profile after single injection of 15mg/kg of Compound 7 in human lung carcinoma H226 xenograft in CD-I nude mice is shown in Figure 10.
- EXAMPLE 22 IN VIVO ABILITY OF COMPOUND 7 TO MODULATE GENE EXPRESSION OF MTF-I, HIF- l ⁇ , MMP2 AND VEGFR2 IN A NSLC CANCER XENOGRAFT MODEL
- RNA w as extracted from 30 mg of tumour tissue using Rneasy Mini kit (QIAGEN, Valencia, CA).
- VMD microvessel density
- EXAMPLE 24 IN VITRO ABILITY OF COMPOUND 7 TO INHIBIT CELL GROWTH IN HUVEC CELLS
- HAVEC Human Umbilical Vein Endothelial Cells
- cell viability w as quantified using the XTT (sodium 3 ⁇ -[l-(phenylamino-carbonyl)-3,4-tetrazolium]-bis (4-methox ⁇ -6-nitro) benzene sulfonic acid hydrate) colorimetric assay (Roche Applied Science, Penzberg, German ⁇ " ) according to manufacturer ' s instructions.
- the plates were further incubated 15 at 37 0 C for 2 hours and the absorbance of each well w as measured by a multi-well spectrophotometer (BioTek Instruments Inc., Winooski, VT) at 460 nm. The data were adjusted relative to the blank and were expressed as a percentage of cell growth compared to the DMSO control.
- HUVEC cells (6 x 10 4 /well) were seeded in 6-w ell plates overnight before being treated with 0.5 ⁇ M of Compound 7 or 5 ⁇ M of the structurally related negative control compound from Example 79 with or without the presence of 100 ⁇ M of ZnCb in a total volume of 2 mL growth medium. After incubation of the cells at 37 0 C for 24 hours, the cells w ere trypsinized and resuspended in growth media to 3 x ICrVmL. One hundred micro litres of cell suspension (3 x 10 4 /well) were plated onto BD GFR Matrigel-coated 96-well plates and incubated for 2 hours. The coating procedure was performed according to the manufacturer ' s Thin Gel Method (BD Biosciences, Bedford. MA). The tube formation w as assessed using an inverted light microscope at 4OX magnification.
- MTF-I metal transcription factor 1
- EXAMPLE 16 PREVENTION OF TUMOR GROWTH IN HUMAN XENOGRAFT MODELS WITH COMPOUND 7
- Human lung carcinoma H226, H460 and HOP92, and human colon carcinoma HT-29 cells were employed. Cancer cells were injected into CD-I athymic mice (Charles River Laboratories) at the flank. When the tumor size reached 70-100 mm the mice w ere treated with Compound 7 or vehicle control administered intravenously for 2 cycles of 5 consecutive days with a 5-10 day break between cycles.
- Figure 15A shows the decrease in tumor growth in the model using H226 lung carcinoma cells and treatment with 15 mg/kg Compound 7 or vehicle control.
- Figure 15B shows the decrease in tumor growth in the model using HOP92 lung carcinoma cells and treatment with 10 mg/kg Compound 7 or vehicle control.
- Figure 15C shows the decrease in tumor growth in the model using H460 lung carcinoma cells and treatment with 7.5 mg/kg Compound 7 or vehicle control (1 cycle).
- Figure 15D shows the decrease in tumor growth in the model using H226 lung carcinoma cells and treatment with 10 mg/kg Compound 7 or vehicle control. All results were significant p ⁇ 0.05.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Bioinformatics & Cheminformatics (AREA)
Abstract
L'invention porte sur des composés 2-indolylimidazo[4,5-d]phénanthroline de formule (I) capables d'inhiber l'angiogenèse. L'invention porte également sur des procédés d'inhibition de l'angiogenèse utilisant des composés de formule (I), ainsi que sur des procédés et des utilisations des composés de formule (I) dans le traitement de maladies et troubles associés à l'angiogenèse tels que le cancer, la dégénérescence maculaire liée à l'âge (DMA), la rétinopathie diabétique et l'occlusion veineuse rétinienne.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15970509P | 2009-03-12 | 2009-03-12 | |
US61/159,705 | 2009-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010102393A1 true WO2010102393A1 (fr) | 2010-09-16 |
Family
ID=42727745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2010/000337 WO2010102393A1 (fr) | 2009-03-12 | 2010-03-12 | Dérivés de 2-indolylimidazo[4,5-d]phénanthroline et leur utilisation pour inhiber l'angiogenèse |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010102393A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102276607A (zh) * | 2011-05-26 | 2011-12-14 | 山西大学 | 一种咪唑[4,5-f]并1,10-邻菲罗啉衍生物及其制备方法和用途 |
WO2015051302A1 (fr) * | 2013-10-04 | 2015-04-09 | Aptose Biosciences Inc. | Compositions et procédés de traitement de cancers |
US10080739B2 (en) | 2003-11-14 | 2018-09-25 | Aptose Biosciences Inc. | Aryl imidazoles and their use as anti-cancer agents |
CN110028437A (zh) * | 2019-01-30 | 2019-07-19 | 浙江农林大学暨阳学院 | 一种微波促进制备2-苯基-3-醛基吲哚类化合物的方法 |
US11149047B2 (en) | 2017-10-30 | 2021-10-19 | Aptose Biosciences, Inc. | Aryl imidazoles for treatment of cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005047266A1 (fr) * | 2003-11-14 | 2005-05-26 | Lorus Therapeutics Inc. | Imidazoles d'aryle et leur utilisation comme agents anticancereux |
WO2006126177A2 (fr) * | 2005-05-25 | 2006-11-30 | Genesense Technologies Inc. | Derives de 2-indolyl imidazo[4,5-d]phenanthroline et utilisation dans le traitement du cancer |
-
2010
- 2010-03-12 WO PCT/CA2010/000337 patent/WO2010102393A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005047266A1 (fr) * | 2003-11-14 | 2005-05-26 | Lorus Therapeutics Inc. | Imidazoles d'aryle et leur utilisation comme agents anticancereux |
WO2006126177A2 (fr) * | 2005-05-25 | 2006-11-30 | Genesense Technologies Inc. | Derives de 2-indolyl imidazo[4,5-d]phenanthroline et utilisation dans le traitement du cancer |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10080739B2 (en) | 2003-11-14 | 2018-09-25 | Aptose Biosciences Inc. | Aryl imidazoles and their use as anti-cancer agents |
CN102276607A (zh) * | 2011-05-26 | 2011-12-14 | 山西大学 | 一种咪唑[4,5-f]并1,10-邻菲罗啉衍生物及其制备方法和用途 |
CN102276607B (zh) * | 2011-05-26 | 2012-10-17 | 山西大学 | 一种咪唑[4,5-f]并1,10-邻菲罗啉衍生物及其制备方法和用途 |
WO2015051302A1 (fr) * | 2013-10-04 | 2015-04-09 | Aptose Biosciences Inc. | Compositions et procédés de traitement de cancers |
WO2015051304A1 (fr) * | 2013-10-04 | 2015-04-09 | Aptose Biosciences Inc. | Compositions, biomarqueurs et leur utilisation dans le traitement du cancer |
US9567643B2 (en) | 2013-10-04 | 2017-02-14 | Aptose Biosciences Inc. | Compositions and methods for treating cancers |
EP3650023A1 (fr) * | 2013-10-04 | 2020-05-13 | Aptose Biosciences Inc. | Compositions pour le traitement de cancers |
US11104957B2 (en) | 2013-10-04 | 2021-08-31 | Aptose Biosciences, Inc. | Compositions and methods for treating cancers |
US11149047B2 (en) | 2017-10-30 | 2021-10-19 | Aptose Biosciences, Inc. | Aryl imidazoles for treatment of cancer |
CN110028437A (zh) * | 2019-01-30 | 2019-07-19 | 浙江农林大学暨阳学院 | 一种微波促进制备2-苯基-3-醛基吲哚类化合物的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2797919B1 (fr) | Pyridophthalazinones tétra ou pentacycliques fusionnés à utiliser en tant qu'inhibiteurs de parp | |
CA3144859C (fr) | Derives de quinazoline-4-one utiles pour le traitement de maladies et de troubles associes a braf | |
JP6440212B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
JP2013500255A (ja) | 自食作用の強力な小分子阻害剤、およびそれの使用方法 | |
JP2013500255A5 (fr) | ||
BR112012018415A2 (pt) | composto, composição, métodos de preparar uma composição e de tratamento, e, uso de um composto. | |
AU2017247282B2 (en) | Nitrogen heterocyclic tryptamine ketone derivative and application as IDO1 and/or TDO inhibitor | |
EP2826780B1 (fr) | Dérivés de thieno[2,3-d]pyridazine et leur utilisation thérapeutique pour l'inhibition de la protéine kinase | |
CA2515102A1 (fr) | Compositions pharmaceutiques comportant des derives thieno[2,3-c]pyridine et utilisation de ces compositions | |
US20140275711A1 (en) | 1-(Arylmethyl)-5,6,7,8-tetrahydroquinazolline-2,4-diones and Analogs and the Use Thereof | |
WO2010102393A1 (fr) | Dérivés de 2-indolylimidazo[4,5-d]phénanthroline et leur utilisation pour inhiber l'angiogenèse | |
US20190231735A1 (en) | Methods for treating cancer | |
JP2018514557A (ja) | Stat3経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法 | |
WO2020228635A1 (fr) | Inhibiteur de kinase egfr et son utilisation dans la préparation d'un médicament anticancéreux | |
JP2005504793A (ja) | Rafキナーゼ阻害剤としてのヘテロサイクルカルボキサミド誘導体 | |
EP3600451A1 (fr) | Agents pour différencier des cellules souches et traiter un cancer | |
CN111655256B (zh) | 包含adam9抑制剂化合物的组合物 | |
US20070191400A1 (en) | Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives | |
CN101007802A (zh) | Hedgehog信号转导途径介质、其相关组合物以及应用 | |
US9309247B2 (en) | 2-substituted imidazo[4,5-D]phenanthroline derivatives and their use in the treatment of cancer | |
AU2022250102B2 (en) | 3,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitors | |
AU2018244449B2 (en) | Agents for differentiating stem cells and treating cancer | |
WO2007000771A2 (fr) | Derives de la quinazolinone fondue et leurs utilisations | |
WO2022197913A1 (fr) | Dérivés bicycliques pouvant être utilisés pour traiter le cancer | |
JP2024047569A (ja) | Mek阻害剤としての3,4-ジヒドロ-2,7-ナフチリジン-1,6(2h,7h)-ジオン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10750279 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10750279 Country of ref document: EP Kind code of ref document: A1 |